In addition, we also analyzed the transcriptomes of tumor tissues and compared them with clinical responses in cohorts of melanoma patients receiving ACT or anti‐PD‐1 therapy.[21, 22] As shown in Figure 1d, expression of the monocyte signature gene CD14 was elevated in the patient groups exhibiting partial response (PR) or complete response (CR) relative to the group of patients with progressive disease (PD). The gene discussed is PDCD1; the disease is melanoma.